What's Going On With Neurocrine Biosciences Stock Today?
Portfolio Pulse from Vandana Singh
Neurocrine Biosciences Inc (NASDAQ:NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH). The study met its primary endpoint at Week 24, demonstrating that treatment with crinecerfont resulted in a statistically significant reduction in daily glucocorticoid dose versus placebo. The company's shares are up 7.82% at $118.21.
September 12, 2023 | 6:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences' positive Phase 3 study results for crinecerfont have led to a 7.82% increase in the company's stock price.
The positive results from the Phase 3 study of crinecerfont, a drug being developed by Neurocrine Biosciences, have likely boosted investor confidence in the company's ability to bring the drug to market. This has resulted in a significant increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100